ONL Therapeutics Completes Enrollment for Phase 2 GALAXY Trial of Xelafaslatide
· GlobeWire Daily Editorial Desk · Source: www.prnewswire.com

Image: ONL Therapeutics, Inc. · Photo source · Resized and letterboxed to 16:9; no AI generation
ONL Therapeutics announced the completion of patient enrollment for its global Phase 2 GALAXY clinical trial. The study evaluates the efficacy and safety of xelafaslatide in treating geographic atrophy (GA) linked to dry age-related macular degeneration (AMD).
Trial Overview and Goals
- Participant count: Over 324 patients enrolled across the U.S., Canada, and Europe.
- Study drug: Xelafaslatide (formerly ONL1204), an investigational small-molecule Fas inhibitor.
- Mechanism: Designed to protect retinal cells, such as photoreceptors, from Fas-mediated cell death.
- Administration: Intravitreal injection with treatment frequencies tested at every 12 or 24 weeks.
Research Methodology
Researchers are measuring the primary endpoint at 48 weeks, specifically tracking the growth rate of the GA lesion area using fundus autofluorescence (FAF). Additional assessments are scheduled to continue through 72 weeks. The trial design follows positive safety and efficacy signals observed during a previous Phase 1b study.
Next Steps
With recruitment finalized, the company expects to release topline data for the 48-week primary endpoint in the fourth quarter of 2027. Patients and healthcare providers interested in verifying trial details or tracking future results can reference clinical trial identifier NCT06659445 on official registry platforms.
Geographic atrophy remains a leading cause of vision loss globally, and this trial aims to provide a treatment option that may reduce the current clinical burden for patients.
AI-assisted reporting; source claims are attributed and have not been independently verified.



